Literature DB >> 22290075

4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity.

Robert L Hudkins1, Allison L Zulli, Reddeppa reddy Dandu, Ming Tao, Kurt A Josef, Lisa D Aimone, R Curtis Haltiwanger, Zeqi Huang, Jacquelyn A Lyons, Joanne R Mathiasen, Rita Raddatz, John A Gruner.   

Abstract

Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H(3)R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H(3)R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290075     DOI: 10.1016/j.bmcl.2012.01.026

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Early identification of hERG liability in drug discovery programs by automated patch clamp.

Authors:  Timm Danker; Clemens Möller
Journal:  Front Pharmacol       Date:  2014-09-02       Impact factor: 5.810

2.  Carbene-catalyzed enantioselective annulation of dinucleophilic hydrazones and bromoenals for access to aryl-dihydropyridazinones and related drugs.

Authors:  Bivas Mondal; Rakesh Maiti; Xing Yang; Jun Xu; Weiyi Tian; Jia-Lei Yan; Xiangyang Li; Yonggui Robin Chi
Journal:  Chem Sci       Date:  2021-05-17       Impact factor: 9.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.